Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07248228 · ClinicalTrials.gov registry record · Phase 2
Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
A Phase 2 study, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT07248228 is a Phase 2 study that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 90 participants.
The verdict
NCT07248228, a Phase 2 study, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.
Interventions
- DRUG Memantine
- RADIATION MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT))
- RADIATION HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT))
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-07 |
| Est. Completion | 2028-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07248228
The ClinicalTrials.gov registry entry for NCT07248228 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Memantine is the first listed.
NCT07248228 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07248228 about?
NCT07248228 is a clinical study titled "Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)". Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve ...
What is the current status of trial NCT07248228?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-07. Estimated completion is 2028-11.
What interventions are being tested in trial NCT07248228?
The interventions under investigation include: Memantine (DRUG), MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT)) (RADIATION), HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT)) (RADIATION).
Who is sponsoring clinical trial NCT07248228?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.